Literature DB >> 17082664

Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus.

Zhongjie Ma1, Fangqi Chen, Michael P Madaio, Philip L Cohen, Robert A Eisenberg.   

Abstract

Chronic graft-vs-host (cGVH) disease is induced in nonautoimmune mice by the transfer of alloreactive T cells that recognize foreign MHC class II. It closely resembles systemic lupus erythematosus, with antinuclear Abs and immune-mediated nephritis. Recent work has implicated TLRs, particularly TLR9, in the recognition of certain autoantigens in vitro and in vivo. To explore further the role of TLR9 in systemic autoimmunity, we induced cGVH disease in C57BL/6 (B6) mice lacking TLR9, including B6 mice expressing the anti-DNA-encoding IgH transgenes 3H9 or 56R (B6.3H9.TLR9(-/-), B6.56R.TLR9(-/-)). We found that cGVH disease caused breakdown of B cell tolerance to chromatin and DNA in TLR9(-/-) recipients of alloreactive cells, yet that nephritis was less severe and that some autoantibody titers were lower compared with B6-cGVH controls. Spleen lymphocyte analysis showed that cGVH disease strikingly depleted marginal zone B cells in B6 mice, but did not influence T cell subsets in either B6 or B6-TLR9(-/-) hosts. B6.56R.TLR9(-/-) mice had less spontaneous production of autoantibodies than B6.56R mice, but there were no significant differences between B6.56R and B6.56R.TLR9(-/-) postinduction of cGVH disease. Taken together, these results suggested that TLR9 may worsen some aspects of systemic autoimmunity while alleviating others.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082664     DOI: 10.4049/jimmunol.177.10.7444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  The role of toll-like receptors in systemic lupus erythematosus.

Authors:  Adeeb H Rahman; Robert A Eisenberg
Journal:  Springer Semin Immunopathol       Date:  2006-09-19

2.  Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity.

Authors:  Sapna Trivedi; Eric L Greidinger
Journal:  Therapy       Date:  2009-05-01

Review 3.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

4.  Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.

Authors:  C K Wong; P T Y Wong; L S Tam; E K Li; D P Chen; C W K Lam
Journal:  Clin Exp Immunol       Date:  2009-10-16       Impact factor: 4.330

5.  T cell CD3ζ deficiency enables multiorgan tissue inflammation.

Authors:  Guo-Min Deng; Jessica Beltran; Chen Chen; Cox Terhorst; George C Tsokos
Journal:  J Immunol       Date:  2013-08-26       Impact factor: 5.422

6.  The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity.

Authors:  Jacquelyn A Gorman; Christian Hundhausen; John S Errett; Amy E Stone; Eric J Allenspach; Yan Ge; Tanvi Arkatkar; Courtnee Clough; Xuezhi Dai; Socheath Khim; Kathleen Pestal; Denny Liggitt; Karen Cerosaletti; Daniel B Stetson; Richard G James; Mohamed Oukka; Patrick Concannon; Michael Gale; Jane H Buckner; David J Rawlings
Journal:  Nat Immunol       Date:  2017-05-29       Impact factor: 25.606

7.  The TYK2-P1104A Autoimmune Protective Variant Limits Coordinate Signals Required to Generate Specialized T Cell Subsets.

Authors:  Jacquelyn A Gorman; Christian Hundhausen; Mackenzie Kinsman; Tanvi Arkatkar; Eric J Allenspach; Courtnee Clough; Samuel E West; Kerri Thomas; Ahmet Eken; Socheath Khim; Malika Hale; Mohamed Oukka; Shaun W Jackson; Karen Cerosaletti; Jane H Buckner; David J Rawlings
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

8.  Toll-like receptors and innate immune responses in systemic lupus erythematosus.

Authors:  Robert Lafyatis; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.